Background: Guidelines recommend mediastinal lymph node sampling as the fi rst invasive test in patients with suspected lung cancer with mediastinal lymphadenopathy without distant metastases, but there are no comparative effectiveness studies on how test sequencing affects outcomes. The objective was to compare practice patterns and outcomes of diagnostic strategies in patients with lung cancer. Methods: The study included a retrospective cohort of 15,316 patients with lung cancer with regional spread without distant metastases in the Surveillance, Epidemiology, and End Results or Texas Cancer Registry Medicare-linked databases. If the fi rst invasive test involved mediastinal sampling, patients were classifi ed as receiving guideline-consistent care; otherwise, they were classifi ed as receiving guideline-inconsistent care. We used propensity matching to compare the number of tests performed and multivariate logistic regression to compare the frequency of complications. Results: Twenty-one percent of patients had guideline-consistent diagnostic evaluations. Among patients with non-small cell lung cancer, 44% never had mediastinal sampling. Patients who had guideline-consistent care required fewer tests than those with guideline-inconsistent care ( P , .0001), including thoracotomies (49% vs 80%, P , .001) and CT image-guided biopsies (9% vs 63%, P , .001), although they had more transbronchial needle aspirations (37% vs 4%, P , .001). The consequence was that patients with guideline-consistent care had fewer pneumothoraxes (4.8% vs 25.6%, P , .0001), chest tubes (0.7% vs 4.9%, P , .001), hemorrhages (5.4% vs 10.6%, P , .001), and respiratory failure events (5.3% vs 10.5%, P , .001). Conclusions: Guideline-consistent care with mediastinal sampling fi rst resulted in fewer tests and complications. We found three quality gaps: failure to sample the mediastinum fi rst, failure to sample the mediastinum at all in patients with non-small cell lung cancer, and overuse of thoracotomy.
I n patients with suspected lung cancer without distant metastases, assessment of the mediastinal lymph nodes is important because the status of the lymph nodes will help the physician to determine whether the disease is surgically resectable. 1 Because of the lim ited accuracy of both CT and PET scanning, current evidence-based guidelines recommend that patients with mediastinal adenopathy by CT or PET scan undergo lymph node sampling to ensure accurate staging. [1] [2] [3] [4] However, signifi cant discordance may exist between what is recommended in evidence-based guidelines and what is actually done in practice. Previous studies of patients with non-small cell lung cancer (NSCLC) found that mediastinoscopy is infrequently performed, and even then, lymph nodes are biopsied in , 50% of cases. 5, 6 Alternative methods of mediastinal lymph node sampling, such as transbronchial needle aspiration (TBNA), have also been underused partly because of inadequate fellowship training. [7] [8] [9] [10] Although these studies demonstrate that mediastinal sampling techniques have been underused, an equally important question is how mediastinal sampling techniques are used in practice. Multiple evidence-based guidelines recommend mediastinal lymph node sampling as the fi rst invasive diagnostic procedure in patients Joint Committee on Cancer nodal staging was not recorded; therefore, it was not possible to further stratify patients into N1 vs N2 vs N3 status. For patients in SEER from 2004 or later, precise TNM staging could be obtained.
Diagnostic and Staging Strategy
The type and sequencing of invasive tests used for diagnosis and staging were determined by Current Procedural Terminology and International Classifi cation of Diseases, Ninth Edition , codes (e- Table 1 ). Invasive tests were defi ned as CT image-guided needle biopsy, bronchoscopy, endoscopy with ultrasound-guided needle aspiration, mediastinoscopy, or thoracotomy. Only tests done within the 6 months preceding the initiation of treatment were considered. Patients were placed into groups based on their diagnostic testing sequence: (1) evaluation consistent with guidelines, some form of mediastinal sampling done fi rst; (2) evaluation inconsistent with guidelines, NSCLC present, mediastinal sampling performed on the second or later biopsy; (3) evaluation inconsistent with guidelines, NSCLC present, mediastinal sampling never done; and (4) evaluation inconsistent with guidelines, small cell lung cancer. Mediastinal sampling procedures were defi ned as bronchoscopy with TBNA or endobronchial ultrasound (EBUS)-guided TBNA, endoscopy with ultrasound-guided needle aspiration, mediastinoscopy, thoracoscopy, or thoracotomy with mediastinal lymph node sampling (see e-Appendix 1 for details on categories and criteria).
Outcomes
The primary outcome was whether the evaluation strategy was consistent with guidelines. Secondary outcomes were whether mediastinal lymph node sampling was ever performed prior to treatment in patients with NSCLC, complications related to the diagnostic evaluation, and the number of invasive diagnostic tests performed. We used a methodology similar to that previously published to identify complications, including pneumothorax, hemorrhage, and respiratory failure. 18 For thoracotomy, any hemorrhage or respiratory failure occurring within 14 days of surgery was considered a complication. For all other procedures, complications were only counted if they occurred up to 1 day after the procedure. We conducted a subset analysis of patients in SEER from 2004 and later to assess the impact of T and N stage on practice patterns. We also conducted an exploratory analysis to assess the relationship among diagnostic practice patterns, subsequent treatment modalities used, and survival.
Statistical Analysis
Characteristics of patients and outcomes were compared using x 2 test for categorical variables; t tests for continuous, normally distributed variables; and Wilcoxon rank sum test for nonnormally distributed variables. We used multivariate logistic regression to analyze factors associated with complications due to diagnostic testing. We decided a priori that variables signifi cantly associated with outcomes at the 0.2 level in univariate analysis would be considered candidate variables for multivariate analysis. Backward selection was used to retain only variables with a level of significance , .05. The number of invasive tests performed was not normally distributed, so we used propensity scores to match patients who had guideline-consistent care with mediastinal sampling fi rst with counterparts who had mediastinal sampling performed second or later. The conditional probability to have guideline-consistent care was estimated by logistic regression analysis incorporating the following variables: age, sex, race, year of diagnosis, Charlson comorbidity index, T stage, geographic region, and cancer type. All statistical analyses were performed at a signifi cance level of .05. All with suspected lung cancer with mediastinal adenopathy without distant metastases because the procedure can be used for both diagnosis and staging. [2] [3] [4] [11] [12] [13] [14] [15] [16] However, to our knowledge, only one single-center comparative effectiveness study has evaluated how test sequencing affects outcomes. 17 The goal of the present study was to compare practice patterns and outcomes of diagnostic and staging strategies in patients with lung cancer with mediastinal lymph node involvement without distant metastasis. We hypothesized that peripheral lung mass biopsy often occurs prior to sampling of the mediastinal lymph nodes, contrary to guidelines. We further hypothesized guideline-inconsistent care would result in unnecessary procedures and more complications.
Materials and Methods

Data Source
We performed a retrospective cohort analysis of two datasets: the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) database and the Texas Cancer Registry (TCR). The registry data have been linked to Medicare claims and 2000 US Census data. We compared the registries and analyzed practice patterns and outcomes. This study was approved by institutional review board 4, and a waiver of informed consent was obtained.
Study Participants
The cohort comprised patients with lung cancer with regional spread to the hilar or mediastinal lymph nodes without distant metastases. The algorithms and search results are shown in Figure 1 (see e- Table 1 For subsequent analysis, therefore, we combined the two registries and controlled for geographic region.
Patient characteristics for the combined cohort are shown in Table 1 . Of the 15,931 eligible patients, 615 (4%) had no Medicare data, indicating that any diagnostic testing was performed. The remaining 15,316 patients (96%) had Medicare data, and this group comprised the fi nal study cohort.
Practice Patterns and Consistency With Guidelines
Only 21% of patients had an evaluation consistent with guidelines, with mediastinal sampling done fi rst ( Fig 2 ) . Of all patients with NSCLC, 44% never had data were analyzed with SAS version 9.2 (SAS Institute Inc) statistical software.
Results
SEER and TCR Medicare Cohorts
A total of 12,363 patients from the SEER and 3,658 patients from the TCR Medicare datasets met the inclusion criteria ( Fig 1 ) . We compared the characteristics of the patients in SEER and TCR, practice patterns, and lung cancer types (e- Table 2 ). Because of the large sample size, P values were signifi cant, but there was little absolute difference between groups. Table 4 ). In multivariate analysis ( Table 5 ), for the outcome of any of these complications on a per-patient basis, guideline-consistent care was associated with a mediastinal sampling prior to treatment. The most common fi rst invasive diagnostic test was bronchoscopy without TBNA followed by CT image-guided biopsy ( Table 2 ) .
Complications
On a per-procedure basis, the incidence of complications was different between groups ( Strata with Յ 10 patients were suppressed per National Cancer Institute policy and are reported as , 11 to ensure confi dentiality. A total of 50 patients with T0 disease have been included in the T1 category to maintain confi dentiality because there were too few patients with T0 disease to report them separately while maintaining confi dentiality. c Poverty is the percentage of the population in the patient's census tract living below the poverty level. Note that this does not mean that the patient's income is below the poverty line, just that the patient is living in a census tract with that level of poverty. d Percentage of patients with , 12 y education is the percentage of the population in their census tract who did not graduate from high school. e Refers to the physician who ordered or performed the fi rst invasive diagnostic test. For bronchoscopy and surgical procedures, this was the physician performing the procedure. For CT image-guided biopsy, this was the referring physician. Internal medicine includes family practice and all subspecialties of internal medicine other than oncology and pulmonary medicine. Surgery includes all other subspecialties of surgery other than thoracic and cardiothoracic. Thoracic surgery and cardiothoracic surgery are included under thoracic surgery. ( Fig 3 ) .
Subset Analysis Using SEER 2004 and Later Data With Precise T and N Staging
Practice patterns and consistency with guidelines for patients in SEER from 2004 to 2007 are shown in Figure 4 . Only 19% of patients had guidelineconsistent care with mediastinal sampling fi rst. Only 52% of patients with NSCLC ever had mediastinal sampling prior to treatment. The frequency of guidelineconsistent care varied according to stage, with patients with stage II disease having guideline-consistent care more frequently ( P , .001) ( Table 7 ) . Among patients with NSCLC who did not have mediastinal sampling lower risk of complications (OR, 0.42; 95% CI, 0.37-0.48; P , .0001).
Part of the difference between groups was due to the type of tests ordered. Patients receiving guidelineconsistent care underwent fewer CT image-guided biopsies than those who had mediastinal sampling done second (9% vs 64%, P , .001) ( Table 3 ) and had fewer bronchoscopies without TBNA (5% vs 70%, P , .001). As a result, far fewer pneumothoraxes occurred in the guideline-consistent group ( P , .001) ( Table 4 ) .
Patients receiving guideline-consistent care also had fewer episodes of hemorrhage and respiratory failure than those who had mediastinal sampling done in a second or later test ( P , .001) ( Table 4 ) because patients with guideline-consistent care underwent fewer thoracotomies (49% vs 80%, P , .001). Instead, patients in the guideline-consistent group had bronchoscopy with TBNA or mediastinoscopy. Patients who never had mediastinal lymph node sampling still had more pneumothoraxes than the guideline-consistent group, but they had fewer episodes of respiratory failure and hemorrhage because they never had surgery.
Number of Invasive Tests Performed
Another factor contributing to the incidence of complications on a per-patient basis was the number of invasive tests performed. Patients with guideline- EBUS 5 endobronchial ultrasound; EUS 5 endoscopic ultrasound; TBNA 5 transbronchial needle aspiration. a Strata with Յ 10 patients were suppressed per National Cancer Institute policy and are reported as , 11 to ensure confi dentiality. EUS was done in , 11 patients and, therefore, was included in the bronchoscopy with TBNA 1 EBUS category to protect patient confi dentiality. 68 (24) 857 (29) 843 (23) 179 (24) , (16) .03
Data are presented as No. (%) unless otherwise indicated. See Table 1 and 2 legends for expansion of abbreviations. a P value compares the frequency of testing use between groups on a per-patient basis. For bronchoscopy with TBNA, mediastinoscopy alone, and thoracotomy, the comparison is only between guidelineconsistent care and guideline-inconsistent care with sampling done second or later. b P value compares incidence of complications on a per-procedure basis among guideline-consistent care, guideline-inconsistent care with sampling done second or later, and guideline-inconsistent care with sampling never done.
never had mediastinal sampling prior to treatment. The consequence of not sampling the mediastinum fi rst was unnecessary testing, more thoracotomies, and more complications. We identifi ed three main practice errors: improper sequencing of invasive tests, failure to sample the mediastinum, and overuse of thoracotomy. We cross-validated the fi ndings by using two large, independently collected datasets and found similar results across multiple regions of the country. Both data sources suggest that a guideline-consistent strategy with mediastinal lymph node sampling done fi rst, preferably with EBUS-TBNA, results in fewer tests and complications than alternative approaches, such as CT image-guided biopsy or thoracotomy. This suggestion may seem counterintuitive because the sensitivity of CT image-guided biopsy is 90%, whereas the sensitivity of bronchoscopy for peripheral lesions is 34% if the lesion is , 2 cm and 63% if . 2 cm. 3 However, treatment decisions require both staging information and a tissue diagnosis. CT imageguided biopsy can only lead to a tissue diagnosis, whereas bronchoscopy with EBUS-TBNA provides both staging and diagnostic information. Even if the CT image-guided biopsy fi nding is positive, additional mediastinal sampling is still required if adenopathy is present. However, physicians often approach this problem by thinking in series, asking what the diagnosis is and only later asking what the stage is. This linear thinking has logical appeal and has been ingrained in training programs. The real goal is to answer both staging and diagnosis questions at the same time, essentially working on multiple questions in parallel rather than in series. Thus, multiple guidelines recommend biopsy of the mediastinal lymph nodes fi rst in patients with evidence of nodal disease rather than biopsy of the peripheral mass. [2] [3] [4] [11] [12] [13] [14] [15] [16] A previous single-center retrospective study suggested that a strategy of sampling the mediastinum fi rst resulted in fewer tests and complications than a as the fi rst test, those with stage II disease were more likely to have mediastinal sampling than those with stage IIIA or IIIB disease (67% vs 34% vs 16%, respectively; P , .001).
Diagnostic Strategy, Subsequent Treatment, and Survival
Among patients with stage II NSCLC, those who had mediastinal sampling were more likely to have surgery as part of their treatment (90% vs 96% vs 8% for guideline consistent, guideline inconsistent with sampling second, and mediastinal sampling never done, respectively; P , .001) ( Fig 4 ) . Among patients with stage IIIA NSCLC, surgery was performed more commonly in patients who had mediastinal lymph node sampling than in those who never had sampling (46% vs 68% vs 5%, respectively; P , .001) ( Fig 4 ) .
Patients with NSCLC who had mediastinal sampling survived longer than those who never had mediastinal sampling ( P , .0001) ( Fig 5 ) . In patients with small cell lung cancer, those who had guidelineconsistent care with mediastinal sampling as the fi rst diagnostic test survived longer than those who had guideline-inconsistent care ( P 5 .03) ( Fig 6 ) , but the magnitude of the effect was much smaller.
Discussion
The fi ndings indicate that a signifi cant quality gap exists in the diagnostic evaluation of patients with lung cancer. Quality gaps are defi ned as the difference between the outcomes and processes found in practice and those obtainable using the best current knowledge. 19, 20 We found that in patients with lung cancer with regional spread to the mediastinal lymph nodes without distant metastases, sampling of the mediastinum was performed fi rst as per guidelines in only 21% of patients. Among patients with NSCLC, 44% solely on imaging to stage the mediastinum is false upstaging, leading to missed opportunities for surgery and possibly cure. Conversely, false understaging would lead to unnecessary thoracotomies and complications. 1, 3 This problem of underuse of mediastinal lymph node sampling has been described previously. 5, 21, 22 Studies of patients undergoing surgery for lung cancer have shown a low rate of mediastinal lymph node biopsy. 5, 22 Although there are fewer data on TBNA and EBUS underuse, surveys of pulmonologists and pulmonary fellows have shown that bronchoscopy training varies signifi cantly, and presumably, practice patterns vary accordingly. 9, 10, [23] [24] [25] This is in the context of randomized strategy of sampling peripheral lung masses fi rst. 17 The present study adds to the existing body of knowledge in this area. It confi rms that sampling the mediastinum fi rst is more effective, resulting in fewer tests and complications. To our knowledge, this multicenter study is the fi rst to compare alternative diagnostic and staging strategies and to quantify the differences in outcome. It suggests that a signifi cant quality gap exists in terms of test sequencing in many areas of the country because the mediastinum was sampled fi rst in only 21% of patients.
The second quality gap we found was failure to sample the mediastinum at all. The result of relying thoracotomy. 3, 26, 27, 29 Although thoracotomy allows sampling of the mediastinal lymph nodes, and many guidelines are not explicit about what comprises an optimal strategy for mediastinal lymph node sampling (thoracotomy could technically qualify as guideline consistent), thoracotomy is not an optimal fi rst choice for evaluation of patients with a high probability of N2 or N3 disease. However, the present data suggest that thoracotomy without prior mediastinal lymph node sampling is not uncommon. Thoracotomy was the fi rst invasive test performed in 6% of patients ( Table 2 ). In addition, in patients with NSCLC who did not have mediastinal sampling done fi rst, thoracotomy without prior sampling of the mediastinum was frequently performed ( Table 3 ). The consequence of thoracotomy overuse was a signifi cantly higher incidence of respiratory failure and hemorrhage ( Table 4 ). EBUS-TBNA or mediastinoscopy fi rst with thoracotomy to follow if the nodes are normal are both controlled studies demonstrating that EBUS-TBNA is at least as good as mediastinoscopy and, in some cases, is more effective and less costly than mediastinoscopy. [26] [27] [28] More recent studies suggested that EBUS-TBNA is gaining traction, 25 but how far it has penetrated into the community is not clear. The present study builds on the existing literature in this area by more directly measuring the quality gap. It demonstrates that underuse of mediastinal staging techniques persists despite recent advances, with only 56% of patients with NSCLC ever undergoing mediastinal sampling.
Although problems with improper sequencing of testing and underuse of mediastinal lymph node sampling techniques clearly exist, the present study also highlights a third potential pitfall: being too aggressive, with resulting overuse of thoracotomy. EBUS-TBNA has fewer complications than mediastinoscopy, and mediastinoscopy has fewer complications than caution is warranted when interpreting the results. Alternative explanations would include stage migration, provider effects, patient effects, or lead time bias. Stage migration is particularly relevant in the present study. It occurs when more accurate staging results in higher stage-based survival. 32 For example, a patient superior to proceeding directly to thoracotomy for this patient population. 26, 30 We also found that sampling of the mediastinal lymph nodes was associated with better survival, which is consistent with previous studies of multimodality mediastinal staging. 31 This is clinically plausible, but Similarly, if surgery with lymph node sampling was performed but was not the fi rst test and there was no prior sampling done, then this was classifi ed as not consistent with guidelines. †If a patient received any type of treatment, such as chemotherapy or radiation, without prior lymph node sampling and went on to surgery with lymph node sampling at that time, then this was considered as no lymph node sampling prior to the fi rst treatment. See Figure 1 legend for expansion of abbreviation.
sampling, he or she would be included in the stage II guideline-inconsistent group. This would result in stage migration, meaning that essentially, the guidelineconsistent stage II group will have improved survival with clinical T2N1M0 disease on CT-PET imaging and positive EBUS-TBNA fi ndings for N2 disease would be included in the stage III guideline-consistent group . If the same patient did not have mediastinal and no surgery. Thus, although a small fraction of the patients included in the present study probably did have normal lymph nodes on CT and PET scans and might have been misclassifi ed as receiving guidelineinconsistent care, it is very likely that the magnitude of the quality gap is still signifi cant, even after accounting for this limitation. Another limitation of the dataset arising from the absence of CT and PET imaging data is that we cannot report on patients who had mediastinal adenopathy by CT or PET scan but who truly had N0 disease (ie, false positive). Some of the patients who never had mediastinal sampling probably fell within this category. However, patients who had mediastinal sampling and were subsequently identifi ed as having N0 disease would not show up in the present cohort. Guideline-consistent care would still dictate mediastinal sampling fi rst, preferably by EBUS-TBNA plus transbronchial biopsy and brush and lavage for diagnosis of the mass. The expected diagnostic yield of bronchoscopy for the mass in such cases would vary depending on the location and size of the mass. For central endobronchial lesions, the diagnostic yield would be about 88%; for peripheral lesions . 2 cm, about 63%; and for peripheral lesions , 2 cm, about 34%. 14 Peripheral radial EBUS in those cases would probably increase the yield further to around 70%. 36 Because radial EBUS probes use the same platform as the convex probes used for lymph node sampling, a practical approach is to fi rst do EBUS-TBNA for lymph compared with the guideline-inconsistent stage II group because the guideline-inconsistent group actually contained some patients with stage III disease. Residual confounding resulting from unmeasured patient or provider characteristics also may have affected the association between mediastinal sampling and survival if patients who had sampling were healthier and received care from high-quality providers and centers of excellence.
Although the present study adds to the existing body of evidence, several limitations are important to consider. The dataset was from administrative databases and included Medicare patients only. As such, the fi ndings may not be generalizable to younger patients. In addition, we were limited to patients enrolled in SEER and TCR, so the fi ndings may not be generalizable to sites not providing data to these databases .
Importantly, because these were administrative data, we had no way to verify that the lymph nodes were enlarged on either CT or PET scan. If the lymph nodes were PET scan negative and not enlarged on CT scan (ie, false negative), then mediastinal sampling would not have been warranted by the guidelines. Such patients would go to surgery, and only later would nodal disease be staged. However, previous studies have shown that patients with negative CT and PET scans have a very low incidence of occult N2 disease (around 5%-7%). [33] [34] [35] In addition, the SEER data from 2004 to 2007 indicate that many patients never had mediastinal sampling and yet received IIIA or IIIB staging node sampling and then to follow this with peripheral biopsy using radial EBUS when needed. This EBUS-TBNA/radial EBUS transbronchial biopsy strategy is superior to CT image-guided biopsy of the peripheral lesion, even in this subset of patients, because the CT image-guided biopsy strategy would still require subsequent mediastinal lymph node sampling in all cases (ie, two tests) because the mediastinal stage would be unknown. In contrast, up to 70% of cases using the EBUS-TBNA/radial EBUS transbronchial biopsy strategy would have suffi cient tissue after one test.
Finally, because these are administrative data, we cannot determine which patients were not surgical candidates because of concurrent severe COPD, other comorbidities, or patient preferences. We used the Charlson comorbidity index to adjust for comorbidities, but there probably was residual confounding. No doubt, many of the patients with stage II disease who did not have surgery would fall into this category. However, we restricted the cohort to patients who received treatment. If a patient can have treatment, albeit not surgical, then sampling of the mediastinum is still necessary because radiation and chemotherapy protocols would change signifi cantly depending on the results. In addition, because we cannot be certain about the severity of the comorbidities present, it may be that the excess complications observed on a perprocedure basis were the result of differences in the clinical characteristics of the patients who we could not measure, explaining the observed higher incidence of complications per procedure in the guidelineinconsistent groups. However, if the guidelineinconsistent group with mediastinal sampling second or later had more severe unmeasured comorbidities, it is unlikely that such differences would lead physicians to order more invasive diagnostic tests, which is what occurred. What is more likely is that physicians in the guideline-inconsistent group ordered invasive tests that provided useful information regarding diagnosis but were insuffi cient to fully stage the disease. As such, these physicians had to order another test to develop a treatment plan.
In summary, we found large quality gaps in the diagnosis and staging of patients with lung cancer. The three main quality gaps were (1) failure to sample the mediastinum fi rst in 79% of patients, (2) failure to sample the mediastinum at all in 44% of patients with NSCLC, and (3) overuse of thoracotomy without prior mediastinal lymph node sampling in 6% of patients. Educational initiatives to address this problem should focus on a clear message: In patients with suspected lung cancer with hilar or mediastinal adenopathy without evidence of distant disease, sample the mediastinum fi rst, preferably with EBUS-TBNA. Following this simple dictum will result in lower costs and morbidity because it will eliminate many unnecessary tests and their associated complications.
